Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Headquarters Consolidation Does Not Slow Outside Rent Growth

This article was originally published in The Tan Sheet

Executive Summary

President Obama’s budget requests less headquarters consolidation funding in fiscal 2015. Outside rent spending in the budget request increased from $116.4 million to $120.9 million due to “escalating costs in commercial rent, security, service contracts and utilities,” according to FDA’s congressional justification.

You may also be interested in...



FDA Budget: Compounding Increase Paid With Construction Funding, Efficiencies

Some planned buildings on the White Oak campus for fiscal 2015 would not be funded and savings from program efficiencies would create the $25 million in new funding for compounding oversight, Hamburg tells House committee.

FDA Budget: Compounding Increase Paid With Construction Funding, Efficiencies

Some planned buildings on the White Oak campus for fiscal 2015 would not be funded and savings from program efficiencies would create the $25 million in new funding for compounding oversight, Hamburg tells House committee.

FDA FY 2012 Budget Gives Hamburg Regulatory Science Upgrade A Year Late

Regulatory science improvements, a casualty of last year’s budget process, would be saved in President Obama’s fiscal year 2012 budget, although in part because some of the infrastructure already is under construction.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel